Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage

Ferenc G. Rick, Luca Szalontay, Andrew V Schally, Norman L Block, Mehrdad Nadji, Karoly Szepeshazi, Irving Vidaurre, Marta Zarandi, Magdolna Kovacs, Zoltan Rekasi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: Benign prostatic hyperplasia often affects aging men. Antagonists of the neuropeptide growth hormone-releasing hormone reduced prostate weight in an androgen induced benign prostatic hyperplasia model in rats. Luteinizing hormone-releasing hormone antagonists also produce marked, protracted improvement in lower urinary tract symptoms, reduced prostate volume and an increased urinary peak flow rate in men with benign prostatic hyperplasia. We investigated the influence of a combination of antagonists of growth hormone-releasing hormone and luteinizing hormone-releasing hormone on animal models of benign prostatic hyperplasia. Materials and Methods: We evaluated the effects of the growth hormone-releasing hormone antagonist JMR-132, given at a dose of 40 μg daily, the luteinizing hormone-releasing hormone antagonist cetrorelix, given at a dose of 0.625 mg/kg, and their combination on testosterone induced benign prostatic hyperplasia in adult male Wistar rats in vivo. Prostate tissue was examined biochemically and histologically. Serum levels of growth hormone, luteinizing hormone, insulin-like growth factor-1, dihydrotestosterone and prostate specific antigen were determined. Results: Marked shrinkage of the rat prostate (30.3%) occurred in response to the combination of growth hormone-releasing hormone and luteinizing hormone-releasing hormone antagonists (p <0.01). The combination strongly decreased prostatic prostate specific antigen, 6-transmembrane epithelial antigen of the prostate, interleukin-1β, nuclear factor-κβ and cyclooxygenase-2, and decreased serum prostate specific antigen. Conclusions: A combination of growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist potentiated a reduction in prostate weight in an experimental benign prostatic hyperplasia model. Results suggest that this shrinkage in prostate volume was induced by the direct inhibitory effects of growth hormone-releasing hormone and luteinizing hormone-releasing hormone antagonists exerted through their respective prostatic receptors. These findings suggest that growth hormone-releasing hormone antagonists and/or their combination with luteinizing hormone-releasing hormone antagonists should be considered for further development as therapy for benign prostatic hyperplasia.

Original languageEnglish
Pages (from-to)1498-1504
Number of pages7
JournalJournal of Urology
Volume187
Issue number4
DOIs
StatePublished - Apr 1 2012

Fingerprint

Hormone Antagonists
Growth Hormone-Releasing Hormone
Prostatic Hyperplasia
Gonadotropin-Releasing Hormone
Prostate
Prostate-Specific Antigen
Weights and Measures
Lower Urinary Tract Symptoms
Dihydrotestosterone
Somatomedins
Cyclooxygenase 2
Luteinizing Hormone
Neuropeptides
Serum
Interleukin-1
Androgens
Growth Hormone
Testosterone
Wistar Rats
Animal Models

Keywords

  • gonadotropin-releasing hormone
  • growth hormone-releasing hormone
  • inflammation
  • prostate
  • prostatic hyperplasia

ASJC Scopus subject areas

  • Urology

Cite this

Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. / Rick, Ferenc G.; Szalontay, Luca; Schally, Andrew V; Block, Norman L; Nadji, Mehrdad; Szepeshazi, Karoly; Vidaurre, Irving; Zarandi, Marta; Kovacs, Magdolna; Rekasi, Zoltan.

In: Journal of Urology, Vol. 187, No. 4, 01.04.2012, p. 1498-1504.

Research output: Contribution to journalArticle

Rick, Ferenc G. ; Szalontay, Luca ; Schally, Andrew V ; Block, Norman L ; Nadji, Mehrdad ; Szepeshazi, Karoly ; Vidaurre, Irving ; Zarandi, Marta ; Kovacs, Magdolna ; Rekasi, Zoltan. / Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. In: Journal of Urology. 2012 ; Vol. 187, No. 4. pp. 1498-1504.
@article{89f15d86e40448fc9b6bc03d43c48fc5,
title = "Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage",
abstract = "Purpose: Benign prostatic hyperplasia often affects aging men. Antagonists of the neuropeptide growth hormone-releasing hormone reduced prostate weight in an androgen induced benign prostatic hyperplasia model in rats. Luteinizing hormone-releasing hormone antagonists also produce marked, protracted improvement in lower urinary tract symptoms, reduced prostate volume and an increased urinary peak flow rate in men with benign prostatic hyperplasia. We investigated the influence of a combination of antagonists of growth hormone-releasing hormone and luteinizing hormone-releasing hormone on animal models of benign prostatic hyperplasia. Materials and Methods: We evaluated the effects of the growth hormone-releasing hormone antagonist JMR-132, given at a dose of 40 μg daily, the luteinizing hormone-releasing hormone antagonist cetrorelix, given at a dose of 0.625 mg/kg, and their combination on testosterone induced benign prostatic hyperplasia in adult male Wistar rats in vivo. Prostate tissue was examined biochemically and histologically. Serum levels of growth hormone, luteinizing hormone, insulin-like growth factor-1, dihydrotestosterone and prostate specific antigen were determined. Results: Marked shrinkage of the rat prostate (30.3{\%}) occurred in response to the combination of growth hormone-releasing hormone and luteinizing hormone-releasing hormone antagonists (p <0.01). The combination strongly decreased prostatic prostate specific antigen, 6-transmembrane epithelial antigen of the prostate, interleukin-1β, nuclear factor-κβ and cyclooxygenase-2, and decreased serum prostate specific antigen. Conclusions: A combination of growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist potentiated a reduction in prostate weight in an experimental benign prostatic hyperplasia model. Results suggest that this shrinkage in prostate volume was induced by the direct inhibitory effects of growth hormone-releasing hormone and luteinizing hormone-releasing hormone antagonists exerted through their respective prostatic receptors. These findings suggest that growth hormone-releasing hormone antagonists and/or their combination with luteinizing hormone-releasing hormone antagonists should be considered for further development as therapy for benign prostatic hyperplasia.",
keywords = "gonadotropin-releasing hormone, growth hormone-releasing hormone, inflammation, prostate, prostatic hyperplasia",
author = "Rick, {Ferenc G.} and Luca Szalontay and Schally, {Andrew V} and Block, {Norman L} and Mehrdad Nadji and Karoly Szepeshazi and Irving Vidaurre and Marta Zarandi and Magdolna Kovacs and Zoltan Rekasi",
year = "2012",
month = "4",
day = "1",
doi = "10.1016/j.juro.2011.11.081",
language = "English",
volume = "187",
pages = "1498--1504",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage

AU - Rick, Ferenc G.

AU - Szalontay, Luca

AU - Schally, Andrew V

AU - Block, Norman L

AU - Nadji, Mehrdad

AU - Szepeshazi, Karoly

AU - Vidaurre, Irving

AU - Zarandi, Marta

AU - Kovacs, Magdolna

AU - Rekasi, Zoltan

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Purpose: Benign prostatic hyperplasia often affects aging men. Antagonists of the neuropeptide growth hormone-releasing hormone reduced prostate weight in an androgen induced benign prostatic hyperplasia model in rats. Luteinizing hormone-releasing hormone antagonists also produce marked, protracted improvement in lower urinary tract symptoms, reduced prostate volume and an increased urinary peak flow rate in men with benign prostatic hyperplasia. We investigated the influence of a combination of antagonists of growth hormone-releasing hormone and luteinizing hormone-releasing hormone on animal models of benign prostatic hyperplasia. Materials and Methods: We evaluated the effects of the growth hormone-releasing hormone antagonist JMR-132, given at a dose of 40 μg daily, the luteinizing hormone-releasing hormone antagonist cetrorelix, given at a dose of 0.625 mg/kg, and their combination on testosterone induced benign prostatic hyperplasia in adult male Wistar rats in vivo. Prostate tissue was examined biochemically and histologically. Serum levels of growth hormone, luteinizing hormone, insulin-like growth factor-1, dihydrotestosterone and prostate specific antigen were determined. Results: Marked shrinkage of the rat prostate (30.3%) occurred in response to the combination of growth hormone-releasing hormone and luteinizing hormone-releasing hormone antagonists (p <0.01). The combination strongly decreased prostatic prostate specific antigen, 6-transmembrane epithelial antigen of the prostate, interleukin-1β, nuclear factor-κβ and cyclooxygenase-2, and decreased serum prostate specific antigen. Conclusions: A combination of growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist potentiated a reduction in prostate weight in an experimental benign prostatic hyperplasia model. Results suggest that this shrinkage in prostate volume was induced by the direct inhibitory effects of growth hormone-releasing hormone and luteinizing hormone-releasing hormone antagonists exerted through their respective prostatic receptors. These findings suggest that growth hormone-releasing hormone antagonists and/or their combination with luteinizing hormone-releasing hormone antagonists should be considered for further development as therapy for benign prostatic hyperplasia.

AB - Purpose: Benign prostatic hyperplasia often affects aging men. Antagonists of the neuropeptide growth hormone-releasing hormone reduced prostate weight in an androgen induced benign prostatic hyperplasia model in rats. Luteinizing hormone-releasing hormone antagonists also produce marked, protracted improvement in lower urinary tract symptoms, reduced prostate volume and an increased urinary peak flow rate in men with benign prostatic hyperplasia. We investigated the influence of a combination of antagonists of growth hormone-releasing hormone and luteinizing hormone-releasing hormone on animal models of benign prostatic hyperplasia. Materials and Methods: We evaluated the effects of the growth hormone-releasing hormone antagonist JMR-132, given at a dose of 40 μg daily, the luteinizing hormone-releasing hormone antagonist cetrorelix, given at a dose of 0.625 mg/kg, and their combination on testosterone induced benign prostatic hyperplasia in adult male Wistar rats in vivo. Prostate tissue was examined biochemically and histologically. Serum levels of growth hormone, luteinizing hormone, insulin-like growth factor-1, dihydrotestosterone and prostate specific antigen were determined. Results: Marked shrinkage of the rat prostate (30.3%) occurred in response to the combination of growth hormone-releasing hormone and luteinizing hormone-releasing hormone antagonists (p <0.01). The combination strongly decreased prostatic prostate specific antigen, 6-transmembrane epithelial antigen of the prostate, interleukin-1β, nuclear factor-κβ and cyclooxygenase-2, and decreased serum prostate specific antigen. Conclusions: A combination of growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist potentiated a reduction in prostate weight in an experimental benign prostatic hyperplasia model. Results suggest that this shrinkage in prostate volume was induced by the direct inhibitory effects of growth hormone-releasing hormone and luteinizing hormone-releasing hormone antagonists exerted through their respective prostatic receptors. These findings suggest that growth hormone-releasing hormone antagonists and/or their combination with luteinizing hormone-releasing hormone antagonists should be considered for further development as therapy for benign prostatic hyperplasia.

KW - gonadotropin-releasing hormone

KW - growth hormone-releasing hormone

KW - inflammation

KW - prostate

KW - prostatic hyperplasia

UR - http://www.scopus.com/inward/record.url?scp=84858702550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858702550&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2011.11.081

DO - 10.1016/j.juro.2011.11.081

M3 - Article

VL - 187

SP - 1498

EP - 1504

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -